European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium.
By F. Pacini, M. Schlumberger, H. Dralle, R. Elisei, J. Smit, W. Wiersinga. European Journal of Endocrinology, 2006
2,086 citations recorded by the source corpus.
Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Genetics
View Paper: https://www.semanticscholar.org/paper/9641f28882ce2bf92105a27f145f2d83eed6f6c3
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
In Epidemiology
In Genetics
Citations in the corpus
- Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and Postpartum (2011, methodology): “According to the ATA management guidelines for DTC (258) and the European Thyroid Association (ETA) consensus (259), serum TSH should be maintained indefinitely below 0.”
- Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010, positive): “In the event of inadequate samples, FNAC should be repeated, while in the case of follicular neoplasia, with normal thyroid stimulating hormone (TSH) and ‘cold’ appearance at thyroid scan, surgery should be considered [7, 8].”
- [Papillary and follicular thyroid carcinoma]. (2007, background): “Elle est réservée aux patients âgés de plus de 45 ans, ayant une invasion tumorale au-delà de la capsule thyroïdienne ou dont l’exérèse complète du tissu néoplasique cervical a été impossible, et qui ne fixe pas l’iode 131 [4,9,10].”
- Strategies of radioiodine ablation in patients with low-risk thyroid cancer. (2012, neutral): “Cytologic test not performed 5 (3) 6 (4) 6 (4) 4 (2)”
- Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer (2009, neutral): “In 1996, the American Thyroid Association (ATA) published treatment guidelines for patients with thyroid nodules and DTC (10).”
- 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer (2009, positive): “The 2009 ATA risk stratification system was somewhat different than staging systems proposed by a European Consensus conference (540) and the Latin American Thyroid Society (LATS) (541) which classify patients as either being at very low risk (unifocal, intrathyroidal T1aN0M0), low risk (T1b N0M0, T”
- Long‐term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation (2007, neutral): “3 Range 10–94 10–14 1439 (31) 15–19 999 (22) 20–24 667 (15) 25–29 471 (10) 30–39 596 (13) 40–49 247 (5) 50 176 (4) Cystic content, % 0–25 3282 (71) [25–75 727 (16) [75 528 (12) Unknown 58 (1) TABLE 3 Final Cytologic Diagnoses in 282 Nodules With Aspirates Initially Diagnosed as ‘Insufficient for Dia”
- Guidelines for radioiodine therapy of differentiated thyroid cancer (2008, methodology): “Efforts have been made to harmonise our recommendations with those of the European Thyroid Association guidelines [12], and the lead author of those guidelines has critically reviewed this article.”
- Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer (2015, methodology): “Recombinant human TSH (rhTSH) has been used for remnant ablation as well as for treatment of intermediate- and high-risk DTC in adults (231-233) and may result in a lower absorbed radiation activity to the blood (as much as 1/3 lower) (234).”
- Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2019, background): “The term ‘very low-risk’ is often applied to these patients in the literature [7, 44].”